🔎 Trials Near Me

홈 › 만성 골수단핵구 백혈병 › 텍사스

텍사스의 만성 골수단핵구 백혈병 임상 시험

만성 골수단핵구 백혈병 관련 연구 18개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.

텍사스의 도시

공식 연구 텍스트(영어)

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • The University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04996875

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

  • M D Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT03683433

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

  • MD Anderson Cancer Center, Houston
피험자 모집 중2상건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT06566742

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT03383575

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

  • MD Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07033598

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

  • AIR Care, Dallas
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 8. 12. 업데이트됨 · NCT07143669

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

  • M D Anderson Cancer Center, Houston
피험자 모집 중2/3상건강한 지원자 환영
18세 ~ 70세 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT04708054

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

  • M D Anderson Cancer Center, Houston
피험자 모집 중1/2상
12세 ~ 80세 · 모든 성별 · 2026. 8. 7. 업데이트됨 · NCT05092451

Personalized NK Cell Therapy in CBT

  • M D Anderson Cancer Center, Houston
피험자 모집 중2상
15세 ~ 80세 · 모든 성별 · 2026. 7. 30. 업데이트됨 · NCT02727803

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

  • The University of Texas M. D. Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 15. 업데이트됨 · NCT07128381

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • M D Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 5. 20. 업데이트됨 · NCT03896269

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

  • M D Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 20. 업데이트됨 · NCT04239157

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • University of Texas Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 4. 30. 업데이트됨 · NCT04256317

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

  • M D Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 16. 업데이트됨 · NCT04140487

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • MD Anderson, Houston
피험자 모집 중2상
18세 ~ 66세 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06859424

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

  • MD Anderson Cancer Center, Houston
피험자 모집 중1상
12세 이상 · 모든 성별 · 2026. 3. 16. 업데이트됨 · NCT06994676

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

  • MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 9. 업데이트됨 · NCT06950034

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • MD Anderson Cancer Center, Huston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 8. 26. 업데이트됨 · NCT03850574

ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.